Online First Article



More variety with the Journal of Cachexia, Sarcopenia and Muscle: JCSM Clinical Reports and JCSM Rapid Communications have both gone live


Last year has brought more variety to the still too small publishing world of cachexia, sarcopenia, and frailty. Besides JCSM Clinical Reports,1 now our second open access daughter journal, named JCSM Rapid Communications, has gone live. We have two dedicated websites for these journals—until they become visible in big search databases like PubMed or Scopus, you can find all content of both journals at www.jcsm‐clinical‐ and www.jcsm‐rapid‐ For those who love statistics, JCSM Clinical Reports so far has 3 editorials and 12 original papers and 1 review published, and JCSM Rapid Communications—having started only very recently—has 1 editorial and 2 original papers under its belt. As much as I would like to thank the whole editorial team in Göttingen and Berlin for their hard work in making these journal projects come alive, I would also like to thank the authors of these articles for entrusting us with their academic work and believing us thereby that we make these publications reputable and lasting homes of their work.

For the main JCSM journal, clinical trials,2-6 disease definition and regulatory issues,7-10 epidemiological reports of broad interest,11-13 and significant basic science mechanistic insights14-16 as well as studies on pathophysiology questions17-19 will remain the main domain of what we aim to publish, but there are so many more things that deserve to be published and often only by a small margin don't make it into JCSM. We have a rejection rate for original reports that is >80%. For the best half of these papers, you will now find that we offer publication transfer to JCSM Clinical Reports or JCSM Rapid Communications, which naturally will have a higher acceptance rate, at least in the first few years. For JCSM Clinical Reports, this was about 50% in 2017. Papers that we accepted there included interesting reports on the importance of body mass index in chronic kidney disease20 and cancer,21 diagnostic22 and imaging studies23, and a report on exercise training in cancer patients24 or the social burden of weight loss in lung cancer.25 The first papers of JCSM Rapid Communications are now also online.26, 27 In the long run, we would think that JCSM Clinical Reports will be more clinically oriented as the title suggests and that JCSM Rapid Communications will be more oriented towards the basic science community of the wasting disorders field. We will all see whether it works out this way.

Both journals are open access journals. The world of publishing is full of such journals, and it is sometimes difficult to distinguish valid publication efforts from commercial publications with no academic aim mass published by the so‐called predatory publishers.28 Still, we believe it is the future of most journals where the aim is fast publication and free access for anyone and exclusion of the middle man of publishing (i.e. the publishers) making a healthy living of the distribution of knowledge (mostly funded by the public) to the public. Of course, there are limits to growth for open access journals—particularly in niche areas like ours. We simply have no marketing budget, and our publication—despite its leadership role in the field and good impact factor—is not available in most libraries of the world. Not even the best publisher in the world bundles an open access journal like ours with their general library offer. Also, many researchers favour submitting to what they call ‘normal’ print journals. For the average author that would mean that for publishing in our journal they would not need to pay the author publication charge from their all too limited research budget. Their organization as a whole would then of course pay through the library charge—assuming we make on to their rooster of journals made available to their faculty. We have heard colleagues ask whether such a future is possible for the JCSM mother journal. I don't know the answer to this yet, but a thought process is ongoing to this end. If you have thoughts on this, please let us know your opinion.

Stephan von Haehling is the editor‐in‐chief of both JCSM Clinical Reports and JCSM Rapid Communications. The work as co‐editor‐in‐chief for the JCSM mother journal has made him highly experienced about the field and the world of publishing—we look forward to his successful stewardship and cooperation in the JCSM journal family. Also the JCSM Clinical Reports and JCSM Rapid Communications open access journal will employ an ethical publishing standard similar to that outline for the main journal.29, 30 The journal is self‐published at this stage as Wiley did not want to take on the daughter journals yet. We are confident that this will change soon, and then the publication, editorial work, and readership experience will be fully the same for all three JCSM journals. On the way to success, we hope you join us contributing your work to this important field. Patients with cachexia, sarcopenia, and frailty deserve our work and success, and that requires exchange of information and ideas. We hope to provide with this growing body of journals a forum for this.


The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle.31


1Trippel TD, Ebner N, von Haehling S. The patient above all else: introducing JCSM Clinical Reports a legitimate crown princess, daughter of the Journal of Cachexia, Sarcopenia and Muscle. JCSM Clin Rep 2016;1:e00015.

2Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, Pettersen CH, Fallon M, Fayers P, Fearon K, Kaasa S. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle 2017;8:778–788.

3van de Bool C, Rutten EPA, van Helvoort A, Franssen FME, Wouters EFM, Schols AMWJ. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J Cachexia Sarcopenia Muscle 2017;8:748–758.

4Chan DD, Tsou HH, Chang CB, Yang RS, Tsauo JY, Chen CY, Hsiao CF, Hsu YT, Chen CH, Chang SF, Hsiung CA, Kuo KN. Integrated care for geriatric frailty and sarcopenia: a randomized control trial. J Cachexia Sarcopenia Muscle 2017;8:78–88.

5Connolly B, Salisbury L, O'Neill B, Geneen L, Douiri A, Grocott MP, Hart N, Walsh TS, Blackwood B. Exercise rehabilitation following intensive care unit discharge for recovery from critical illness: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle 2016;7:520–526.

6Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153–161.

7Fearon K, Evans WJ, Anker SD. Myopenia—a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle 2011;2:1–3.

8Anker SD, Morley JE, von Haehling S. Welcome to the ICD‐10 code for sarcopenia. J Cachexia Sarcopenia Muscle 2016;7:512–514.

9Morley JE, Anker SD. Myopenia and precision (P4) medicine. J Cachexia Sarcopenia Muscle 2017;8:857–863.

10Fearon K, Argiles JM, Baracos VE, Bernabei R, Coats A, Crawford J, Deutz NE, Doehner W, Evans WJ, Ferrucci L, Garcia JM, Gralla RJ, Jatoi A, Kalantar‐Zadeh K, Lainscak M, Morley JE, Muscaritoli M, Polkey MI, Rosano G, Rossi‐Fanelli F, Schols AM, Strasser F, Vellas B, von Haehling S, Anker SD. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle 2015;6:272.

11Farkas J, von Haeling S, Kalantar‐Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle 2013;4:173–178.

12Konishi M, Ishida J, Springer J, Anker SD, von Haehling S. Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact. J Cachexia Sarcopenia Muscle 2016;7:515–519.

13von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle 2016;7:507–509.

14Johns N, Stretch C, Tan BH, Solheim TS, Sørhaug S, Stephens NA, Gioulbasanis I, Skipworth RJ, Deans DA, Vigano A, Ross JA, Bathe OF, Tremblay ML, Kaasa S, Strasser F, Gagnon B, Baracos VE, Damaraju S, Fearon KC. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle 2017;8:122–130.

15Lodka D, Pahuja A, Geers‐Knörr C, Scheibe RJ, Nowak M, Hamati J, Köhncke C, Purfürst B, Kanashova T, Schmidt S, Glass DJ, Morano I, Heuser A, Kraft T, Bassel‐Duby R, Olson EN, Dittmar G, Sommer T, Fielitz J. Muscle RING‐finger 2 and 3 maintain striated‐muscle structure and function. J Cachexia Sarcopenia Muscle 2016;7:165–180.

16Narasimhan A, Ghosh S, Stretch C, Greiner R, Bathe OF, Baracos V, Damaraju S. Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J Cachexia Sarcopenia Muscle 2017;8:405–416.

17Inoue A, Cheng XW, Huang Z, Hu L, Kikuchi R, Jiang H, Piao L, Sasaki T, Itakura K, Wu H, Zhao G, Lei Y, Yang G, Zhu E, Li X, Sato K, Koike T, Kuzuya M. Exercise restores muscle stem cell mobilization, regenerative capacity and muscle metabolic alterations via adiponectin/AdipoR1 activation in SAMP10 mice. J Cachexia Sarcopenia Muscle 2017;8:370–385.

18Berger D, Bloechlinger S, von Haehling S, Doehner W, Takala J, Z'Graggen WJ, Schefold JC. Dysfunction of respiratory muscles in critically ill patients on the intensive care unit. J Cachexia Sarcopenia Muscle 2016;7:403–412.

19Molinari F, Pin F, Gorini S, Chiandotto S, Pontecorvo L, Penna F, Rizzuto E, Pisu S, Musarò A, Costelli P, Rosano G, Ferraro E. The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26‐bearing mice. J Cachexia Sarcopenia Muscle 2017;8:954–973.

20O'Driscoll JM, Slee A, Sharma R. Body mass index mortality paradox in chronic kidney disease patients with suspected cardiac chest pain. JCSM Clin Rep 2017;1:e00010.

21Aahlin EK, Irino T, Johns N, Brismar T, Nilsson M, Revhaug A, Lassen K. Body composition indices and tissue loss in patients with resectable gastric adenocarcinoma. JCSM Clin Rep 2017;1:e00013. https://jcsm‐clinical‐‐cr/article/view/13

22Mori T, Fujishima I, Wakabayashi H, Itoda M, Kunieda K, Kayashita J, Nishioka S, Sonoda A, Kuroda Y, Yamada M, Ogawa S. Development, reliability, and validity of a diagnostic algorithm for sarcopenic dysphagia. JCSM Clin Rep 2017;2:e00017. https://jcsm‐clinical‐‐cr/article/view/17

23Patel J, Baruah D, Shahir K. A novel computed tomography method to detect normal from abnormal psoas muscle: a pilot feasibility study. JCSM Clin Rep 2017;1:e00014. https://jcsm‐clinical‐‐cr/article/view/14

24Lonbro S, Farup J, Bentsen S, Voss T, Rittig N, Wang J, Orskov M, Hojris I, Mikkelsen UR. Lean body mass, muscle fibre size and muscle function in cancer patients during chemotherapy and 10 weeks exercise. JCSM Clin Rep 2017;1:e00026. https://jcsm‐clinical‐‐cr/article/view/26

25Rodriguez AM, Braverman J, Aggarwal D, Friend J, Duus E. The experience of weight loss and its associated burden in patients with non-small cell lung cancer: results of an online survey. JCSM Clin Rep 2017;2:e00018. https://jcsm‐clinical‐‐cr/article/view/18

26Busquets S, Marmonti E, Oliva F, Simoes E, Luna D, Sand J, et al. Omega‐3 and omega‐3/curcumin‐enriched fruit juices decrease tumour growth and improve muscle wasting in tumour‐bearing mice. JCSM Rapid Commun 2018;1:e00025. https://jcsm‐rapid‐‐rc/article/view/25

27Klose A, Liu W, Paris N, Forman S, Krolewski J, Nastiuk K, et al. Castration induces satellite cell activation that contributes to skeletal muscle maintenance. JCSM Rapid Commun. 2018;1:e00040. https://jcsm‐rapid‐‐rc/article/view/40

28Moher D, Moher E. Stop predatory publishers now: act collaboratively. Ann Intern Med 2016;164:616–617.

29von Haehling S, Ebner N, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle Clinical Reports. JCSM Clin Rep 2016;1:e00028.

30von Haehling S, Ebner N, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle rapid communications. JCSM Rapid Commun. 2018;1:e00044.

31von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017. J Cachexia Sarcopenia Muscle 2017;8:1081–1083.


Template Design Joomla

Copyright 2018 JCSM